Endothelial cell growth inhibitor (EGI) is a protein produced by capillary endothelial cells which inhibits their growth in an autocrine fashion. EGI will be purified from growth medium conditioned by endothelial cells and used in in vitro and in vivo model systems to test whether this protein can be used to inhibit the formation of new capillaries. This is the first step towards developing a therapy that will be used in the treatment of solid tumors, various retinopathies, psoriasis, arterial occlusive disease and in birth control, all of which either involve neovascularization or growth of endothelial cells themselves.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL037806-01
Application #
3501038
Study Section
Physical Biochemistry Study Section (PB)
Project Start
1986-12-01
Project End
1987-05-31
Budget Start
1986-12-01
Budget End
1987-05-31
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
California Biotechnology, Inc.
Department
Type
DUNS #
City
Mountain View
State
CA
Country
United States
Zip Code
94043